Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says

Zepbound, a weight loss drug, may also benefit individuals with obstructive sleep apnea, according to drugmaker Eli Lilly. The company plans to submit data from trials to the US Food and Drug Administration (FDA) to potentially expand Zepbound’s use for this condition. Obstructive sleep apnea is a disorder where breathing temporarily stops during sleep, often causing fatigue and increasing the risk of other health problems. Studies indicate that weight loss can improve sleep apnea, and preliminary results from trials of Zepbound show improvement in sleep apnea in patients with obesity. Further details will be shared at a medical conference in June.